Vaxcyte (NASDAQ:PCVX) CEO Grant Pickering Sells 22,461 Shares of Stock

Posted by George Bondi on Jun 18th, 2026

Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) CEO Grant Pickering sold 22,461 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total transaction of $1,179,202.50. Following the sale, the chief executive officer owned 474,703 shares of the company’s stock, valued at $24,921,907.50. This trade represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Grant Pickering also recently made the following trade(s):

On Thursday, June 18th, Grant Pickering sold 2,000 shares of Vaxcyte stock. The shares were sold at an average price of $52.50, for a total value of $105,000.00.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded up $0.77 during trading hours on Thursday, reaching $51.44. 2,837,023 shares of the stock were exchanged, compared to its average volume of 1,270,669. The firm has a market capitalization of $7.43 billion, a price-to-earnings ratio of -7.48 and a beta of 1.24. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00. The stock’s fifty day simple moving average is $53.56 and its 200 day simple moving average is $52.70.

Vaxcyte (NASDAQ:PCVX – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same period last year, the business earned ($1.04) earnings per share. Research analysts predict that Vaxcyte, Inc. will post -7.56 EPS for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

A number of hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in Vaxcyte by 33.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares in the last quarter. Meeder Advisory Services Inc. grew its holdings in shares of Vaxcyte by 2.9% during the 1st quarter. Meeder Advisory Services Inc. now owns 8,335 shares of the company’s stock worth $484,000 after purchasing an additional 231 shares in the last quarter. CWM LLC increased its position in shares of Vaxcyte by 9.0% in the fourth quarter. CWM LLC now owns 2,840 shares of the company’s stock worth $131,000 after purchasing an additional 234 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Vaxcyte by 0.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 31,274 shares of the company’s stock worth $1,443,000 after purchasing an additional 252 shares during the period. Finally, Principal Financial Group Inc. raised its stake in Vaxcyte by 7.0% in the first quarter. Principal Financial Group Inc. now owns 5,275 shares of the company’s stock valued at $307,000 after purchasing an additional 343 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PCVX. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. BTIG Research upped their price target on shares of Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vaxcyte presently has an average rating of “Moderate Buy” and an average target price of $86.00.

View Our Latest Analysis on Vaxcyte

About Vaxcyte

(Get Free Report)

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.